Technical Analysis for MYL - Mylan Inc.

Grade Last Price % Change Price Change
grade D 16.9 3.55% 0.58
MYL closed up 3.55 percent on Wednesday, August 5, 2020, on 1.14 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: Aug 6
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical MYL trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
BB Squeeze Ended Range Expansion 0.00%
Outside Day Range Expansion 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Resistance Bearish 3.55%
50 DMA Resistance Bearish 3.55%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Mylan Inc. engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily develops, manufactures, sells, and distributes generic or branded generic pharmaceutical products in tablet, capsule, and injectable or transdermal patch forms, as well as API. It also focuses on developing APIs with non-infringing processes to partner with manufacturers. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable, nebulized, and transdermal products for life-threatening conditions. Its products include EpiPen Auto-Injector to treat severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. The company also manufactures and sells injectable products in various therapeutic areas for the hospital setting; supplies APIs for the manufacture of antiretroviral (ARV) drugs to treat HIV/AIDS; offers finished dosage form (FDF) products in the ARV market; and manufactures non-ARV FDF products, as well as focuses on developing, manufacturing, and commercializing dry powder inhaler delivery platform. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is based in Canonsburg, Pennsylvania.
Health Life Sciences Pharmaceutical Industry Pharmaceuticals Pharmaceuticals Policy Active Pharmaceutical Ingredients HIV/Aids Healthcare Institutions Generic Pharmaceutical Products Disorder Generic Drug Pharmaceutical Wholesalers Drug Manufacturers Injectable Products

Is MYL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 23.11
52 Week Low 12.75
Average Volume 5,696,904
200-Day Moving Average 17.74
50-Day Moving Average 16.58
20-Day Moving Average 16.41
10-Day Moving Average 16.34
Average True Range 0.60
ADX 11.92
+DI 26.38
-DI 15.69
Chandelier Exit (Long, 3 ATRs ) 15.51
Chandelier Exit (Short, 3 ATRs ) 17.47
Upper Bollinger Band 17.10
Lower Bollinger Band 15.73
Percent B (%b) 0.86
BandWidth 8.31
MACD Line 0.03
MACD Signal Line -0.01
MACD Histogram 0.0316
Fundamentals Value
Market Cap 9.06 Billion
Num Shares 536 Million
EPS 1.24
Price-to-Earnings (P/E) Ratio 13.63
Price-to-Sales 1.72
Price-to-Book 1.61
PEG Ratio 1.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.25
Resistance 3 (R3) 18.18 17.65 18.03
Resistance 2 (R2) 17.65 17.31 17.69 17.95
Resistance 1 (R1) 17.28 17.10 17.47 17.35 17.87
Pivot Point 16.75 16.75 16.85 16.79 16.75
Support 1 (S1) 16.38 16.41 16.57 16.45 15.93
Support 2 (S2) 15.85 16.20 15.89 15.85
Support 3 (S3) 15.48 15.85 15.78
Support 4 (S4) 15.55